This article is more than 5 years old. Information may no longer be current.
Top 5 IBD stories you may have missed in January
Click Here to Manage Email Alerts
Healio Gastroenterology and Liver Disease compiled a list of the top five inflammatory bowel disease-related stories posted in January.
Our readers were most interested in new AGA guidelines for ulcerative colitis management, as well as the effect vedolizumab plus corticosteroids had on inducing remission or clinical response in patients with moderately to severely active Crohn’s disease.
AGA releases new ulcerative colitis management guidelines
The American Gastroenterological Association has released new clinical guidelines on the management of patients with mild to moderate ulcerative colitis, focusing on the use of both oral and topical 5-aminosalicylates, rectal corticosteroids and oral budesonide.
Less-conventional therapies such as probiotics, curcumin and fecal microbiota transplantation were not recommended for the treatment of patients with mild to moderate UC. READ MORE.
Anaerobically prepared FMT may be an effective ulcerative colitis treatment
Fecal microbiota transplantation suspensions prepared anaerobically could be an effective treatment for mild-to-moderate ulcerative colitis, according to research published in JAMA.
Samuel P. Costello, MBBS, of the department of gastroenterology at The Queen Elizabeth Hospital in Australia, and colleagues wrote that the success of FMT in treating Clostridium difficile infection has sparked interest in studying it as a treatment for other diseases. Although previous studies have produced varied results, the authors thought this could be due to how the suspensions were processed. READ MORE.
AGA working group releases guide for pregnant women with IBD
The American Gastroenterological Association has published a new clinical care pathway to develop a standardized plan among health care providers who treat women with IBD throughout all stages of family planning.
“In the United States, 1.6 million people have inflammatory bowel disease,” Rajeev Jain, MD, AGAF, FACP, an IBD Parenthood Project program co-chair and a gastroenterologist at Texas Digestive Disease Consultants, told Healio Gastroenterology and Liver Disease. “Of those, roughly half are women, and most will carry the diagnosis during childbearing years, throughout all phases of family planning – trying to conceive, pregnancy and postpartum. Additionally, the number of women with IBD who are voluntarily childless is three times greater than that of the general population, mainly because of lack of information and misperceptions around pregnancy and IBD.” READ MORE.
Entyvio, corticosteroid combination may improve Crohn’s induction response
Using a combination of Entyvio and stable doses of corticosteroids as a baseline therapy may help induce remission or clinical response in patients with moderately to severely active Crohn’s disease, according to research published in Inflammatory Bowel Diseases.
“Guidelines provide only weak recommendations regarding combination induction therapy for CD,” Bruce E. Sands, MD, of the Icahn School of Medicine at Mount Sinai, and colleagues wrote. “Given the limited evidence available to date, further data are needed about therapies that provide benefits when combined with conventional corticosteroid treatment.” READ MORE.
Microbiome conference highlights role microbiota plays in IBD, IBS, obesity
The Gut Microbiome Conference, which was held for the fourth time in October, included plenary lectures, interactive case-based presentations, and panel discussions on topics ranging from the microbiome’s connection to diabetes and obesity, as well as developing diagnostics and treatments for IBD.
Healio Gastroenterology and Liver Disease recently spoke with Mark Pimentel, MD, executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai, and course co-director for the meeting, to discuss the highlights of the conference and what’s next. READ MORE.